Pages that link to "Q73088643"

The following pages link to Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex--a possible mechanism of neuroprotection in major depression? (Q73088643):

Displaying 39 items.

• Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders (Q24632936) (← links)
• Review of pharmacological treatment in mood disorders and future directions for drug development. (Q26853509) (← links)
• Altered excitatory-inhibitory balance within somatosensory cortex is associated with enhanced plasticity and pain sensitivity in a mouse model of multiple sclerosis (Q27303085) (← links)
• Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants (Q28472408) (← links)
• Advances in the treatment of anxiety: targeting glutamate (Q30457479) (← links)
• Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways (Q33595018) (← links)
• Elevated endogenous GABA concentration attenuates glutamate-glutamine cycling between neurons and astroglia (Q33754687) (← links)
• Striatal structure and function in mood disorders: a comprehensive review (Q33777327) (← links)
• Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders (Q34204211) (← links)
• Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission (Q34622363) (← links)
• Modulation of synaptic plasticity by stress and antidepressants (Q34785753) (← links)
• Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression (Q35111592) (← links)
• Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders. (Q35236446) (← links)
• Repeated administration of imipramine modifies GABAergic transmission in rat frontal cortex (Q36781548) (← links)
• Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders (Q37143117) (← links)
• Role of zinc in maternal and child mental health (Q37271539) (← links)
• Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia (Q37425212) (← links)
• Neuroinflammation and comorbidity of pain and depression (Q37432089) (← links)
• Ketamine as antidepressant? Current state and future perspectives (Q37559823) (← links)
• Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases? (Q37783637) (← links)
• Antistress properties of antidepressant drugs and their clinical implications (Q37884805) (← links)
• Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited (Q37891098) (← links)
• Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs (Q37892101) (← links)
• Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity (Q38148183) (← links)
• Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice. (Q39143939) (← links)
• Phenelzine (monoamine oxidase inhibitor) increases production of nitric oxide and proinflammatory cytokines via the NF-κB pathway in lipopolysaccharide-activated microglia cells. (Q39319617) (← links)
• Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. (Q39441772) (← links)
• Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? (Q42399167) (← links)
• Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus (Q44071643) (← links)
• Repeated administration of antidepressants decreases field potentials in rat frontal cortex (Q44535421) (← links)
• Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. (Q46412677) (← links)
• The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant (Q46708775) (← links)
• AMPA GluR-A receptor subunit mediates hippocampal responsiveness in mice exposed to stress (Q48155219) (← links)
• Glutamate level detection by magnetic resonance spectroscopy in patients with post-stroke depression (Q48888139) (← links)
• Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals (Q48932638) (← links)
• Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex (Q51057089) (← links)
• NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course. (Q55330019) (← links)
• Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition (Q80985451) (← links)
• Antinociceptive Effects of the Antidepressant Phenelzine are Mediated by Context-Dependent Inhibition of Neuronal Responses in the Dorsal Horn (Q88647673) (← links)